The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Descending
Mar 2019
Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study
Psychiatry Research
AUTHOR(S)
Mar 2019
Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique
Journal of Psychiatric Practice
AUTHOR(S)
Mar 2019
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
American Journal of Psychiatry
AUTHOR(S)
Sep 2018
Pharmacokinetic evaluation of a one-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia
Journal of Clinical Psychopharmacology
AUTHOR(S)
Jul 2018
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
European Journal of Drug Metabolism and Pharmacokinetics
AUTHOR(S)
Jul 2018
Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the positive and negative syndrome scale - supportive analyses from a phase 3 study
CNS Spectrums
AUTHOR(S)
Jul 2018
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry
Addiction
AUTHOR(S)
May 2018
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial
Drug and Alcohol Dependence
AUTHOR(S)
Apr 2018
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
Schizophrenia Research
AUTHOR(S)
Mar 2018
Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies
Current Medical Research and Opinion
AUTHOR(S)
